Cytotoxic activity of sparfloxacin and its degradation products in mononuclear human blood cells;Analise citotoxica de esparfloxacino e seus produtos de degradaçao em células mononucleares humanas

Revista de Ciencias Farmaceuticas

Volumn 23, Issue 2, 2002, Pages 227-238

  Marona, Hérida Regina Nunes ^c   Schapoval, Elfrides Eva Scherman ^c   Nardi, Nance Beyer ^a,b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c NONE

Author keywords

Antibacterial substances; Cytotoxic activity; Quinolones; Sparfloxacin fluorquinolones

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ARTICLE; CELL CULTURE; CHLAMYDIA; CYTOTOXICITY; DRUG DEGRADATION; DRUG STABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; LEGIONELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONONUCLEAR CELL; MYCOBACTERIUM; MYCOPLASMA; PHOTODEGRADATION; PHOTOREACTIVITY; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIAE; TABLET; ULTRAVIOLET C RADIATION; ULTRAVIOLET IRRADIATION;

EID: 0041930588     PISSN: 01013793     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. ABBAS, A. K.; LICHTMAN, A. H.; POBER, J. S. Cellular and molecular immunology. 4.ed. Philadelphia: W. B. Saunders, 2000. 553p.
2. AUBIER, M. et al. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J. Antimicrob. Chemother., v.37, suppl. A, p.73-82, 1996.
3. COOPER, M. A. et al. In vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J. Antimicrob. Chemother., v.26, n.5, p.667-676, 1990.
4. FERGUSON, J.; DAWE, R. Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. Journal of Antimicrobial Chemotherapy, v.40, Suppl. A, p.93-98, 1997.
5. GOA, K. L.; BRYSON, H. M.; MARKHAM, A. Sparfloxacin: A review of its antibacterial activity, pharmacokinetic properies, clinical efficacy and tolerability in lower respiratory tract infections. Drugs, v.53, n.4, p.700-725, 1997.
6. MARONA, H. R. N. et al. Photodegradation of sparfloxacin and its degradation products isolation using preparative HPLC. Acta Pharm. Turcica, v.44, suppl., p.99, 2002.
7. MARTINDALE: the complete drug reference. 32.ed. London: Pharmaceutical Press, 1999.
8. ROBERTSON, D. G. et al. Mechanistic studies of the phototoxic potential of PD 117596, a quinolone antibacterial compound. Toxicol. Appl. Pharmacol., v.111, n.2, p.221-232, 1991.
9. SHIMADA, J.; NOGITA, T.; ISHIBASHI, Y. Clinical pharmacokinetics of sparfloxacin. Clin. Pharmacokinet., v.25, n.5, p.358-369, 1993.
10. SNEDECOR, G. W. Statistical methods. 5th.ed. Ames: The Iowa State University Press, 1956.
11. SPARFLOXACIN: focus on clinical performance. J. Antimicrob. Chemother., v.37, suppl. A, p.1-160, 1996.
12. SPARFLOXACIN SPARA® ZAGAM®. Drugs Future, v.19, n.5, p.524-526, 1994.
13. SPARFLOXACIN SPARA® ZAGAM®. Drugs Future, v.22, n.5, p.575-577, 1997.
14. SPARFLOXACIN SPARA® ZAGAM®. Drugs Future, v.24, n.5, p.581, 1999.
15. STITES, D. P. Laboratory evaluation of immune competence. In: STITES, D. P.; TERR, A. I.; PARSLOW, T. G. Basic and clinical immunology. 8.ed. Norwalk: Appleton & Langes, 1994.
16. THOMA, K.; KÜBLER, N. Photoinstabilität von Arzneistoffen und ihre analytischen Nachweismöglichkeiten. Die Pharmazie, v.51, n.9, p.919-923, 1996.
17. THOMA, K.; KÜBLER, N. Untersuchungen zur Photostabilität von Gyrazehemmern. Die Pharmazie, v.52, n.7, p.519-529, 1997.
18. TILLOTSON, G. S. Quinolones: structure-activity relationships and future predictions. J. Med. Microbiol., v.44, n.5, p.320-324, 1996.
19. 2. Br. J. Dermatol., v.140, p.784, 1999.
20. TRAYNOR, N. J.; GIBBS, N. K. The phototumorigenic fluorquinolone lomefloxacin photosensitizes pyrimidine dimer formation in human keratinocytes in vitro. Photochem. Photobiol., v.70, n.6, 2000. (In press).
21. VERMEERSCH, G. et al. Evaluation photophysique du pouvoir photosensibilisant de diverses quinolones. J. Pharm. Belg., v.45, n.5, p.299-305, 1990.
22. WAGAI, N.; TAWARA, K. Important role of oxygen metabolites in quinolone antibacterial agent induced cutaneous phototoxicity in mice. Arch. Toxicol., v.65, p.495-499, 1991.
23. WAGAI, N.; TAWARA, K. Possible direct role of reactive oxygens in the cause of cutaneous phototoxicity induced by five quinolones in mice. Arch. Toxicol., v.66, n.6, p.392-397, 1992.
24. WAGAI, N.; YOSHIDA, M.; TAKAYAMA, S. Phototoxic potencial of the new quinolone antibacterial agent levofloxacin in mice. Arzneim. Forsch. Drug Res., v.42, n.3a, p.404-405, 1992.